Syndax Pharmaceuticals (SNDX) Wins Prix Galien Award, But Is The Valuation Case More Compelling Now?

Syndax Pharmaceuticals (SNDX) is back in focus after its acute leukemia therapy Revuforj won the 2026 Prix Galien USA Award for Best Product for Rare or Orphan Diseases.

The award arrives after a choppy period for Syndax Pharmaceuticals’ stock, with the 30 day share price return down 27.5% and the year to date share price return down 36.0%. The 1 year total shareholder return is roughly flat at a decline of 0.5%, suggesting longer term holders have seen far less damage than recent traders and that momentum has been fading into this news.

Compare Syndax Pharmaceuticals with other rare disease and oncology players by scanning the 19 high quality undiscovered gems that analysts often overlook despite stronger fundamentals.

Syndax Pharmaceuticals now trades sharply below both analyst targets and some intrinsic value estimates after that selloff. The next step is to determine whether that gap reflects real risk or an overdone reaction.

Most Popular Narrative: 40.7% Undervalued

Against the last close of $13.63, the most widely followed narrative pegs Syndax Pharmaceuticals at a fair value of $23.00, implying a large valuation gap that hinges on how investors view concentration risk and long term earnings power.

The main thing that has to go right is that Revuforj and Niktimvo continue to scale across additional AML, GVHD, and fibrosis indications, while high R&D and SG&A spending near US$400 million in 2026 eventually converts into sustainable profitability rather than ongoing losses.

See why 2 investors see Syndax Pharmaceuticals as 41% undervalued.

Result: Fair Value of $23.00 (UNDERVALUED)

Still, the narrative can break if Revuforj demand remains soft or if Niktimvo label expansions disappoint, which would leave Syndax Pharmaceuticals carrying high costs without matching revenue.

Find out about the key risks to this Syndax Pharmaceuticals narrative.

Another View: Market Pricing Sends Mixed Signals On Syndax Pharmaceuticals

There is a twist. While the narrative fair value and analyst targets frame Syndax Pharmaceuticals as undervalued on future earnings potential, the current P/S of 4.8x looks expensive next to a fair ratio of 2.9x, even if it trades far below the US Biotechs peer average of 11.6x. Is the discount a bargain or just compensation for risk that P/S is already flagging?

To weigh that question against the broader sector and peer set, it helps to see what the numbers say in a cleaner valuation breakdown and then judge how much volatility you are really comfortable underwriting through See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Seen enough debate about Syndax Pharmaceuticals to feel pulled in both directions? Move quickly, review the underlying data yourself, then weigh the upside case in the 2 key rewards.

Looking for more investment ideas beyond Syndax Pharmaceuticals?

If Syndax Pharmaceuticals has your attention, do not stop there. Broaden your watchlist with targeted stock ideas that match how you like to invest.

• Zero in on mispriced quality by scanning the 33 high quality undervalued stocks that combine stronger fundamentals with more attractive entry points.
• Prioritise resilience first and stress test your portfolio against shocks using the 29 resilient stocks with low risk scores built around sturdier business profiles.
• Build from a position of strength and spot companies with healthier finances through the list of solid balance sheet and fundamentals (24 results) before the crowd catches on.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com